相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rituximab treatment for multiple sclerosis
Benjamin V. Ineichen et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis
Emanuele Pravata et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases
Pierre Durozard et al.
ANNALS OF NEUROLOGY (2020)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Gustavo Luna et al.
JAMA NEUROLOGY (2020)
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Finn Sellebjerg et al.
CNS DRUGS (2020)
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Benedicte Delcoigne et al.
NEUROLOGY (2020)
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders
Olga Ciccarelli et al.
LANCET NEUROLOGY (2019)
Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis
Wallace J. Brownlee et al.
BRAIN (2019)
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
Ester Canto et al.
JAMA NEUROLOGY (2019)
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
Gisa Ellrichmann et al.
JOURNAL OF NEUROLOGY (2019)
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Nicky Dunn et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
Nicky Dunn et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
Carmen Alcala et al.
JOURNAL OF NEUROLOGY (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
Sara Barmettler et al.
JAMA NETWORK OPEN (2018)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Biplanar MRI for the assessment of the spinal cord in multiple sclerosis
Katrin Weier et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
